# Simultaneous Inhibition of MDM2 and XIAP by MX69 Induced Cell Cycle Arrest and Apoptosis in HUH7 and Hep3B Cell Lines

**Authors:** Can Ali Ağca

PMC · DOI: 10.3390/cimb48020177 · 2026-02-04

## TL;DR

MX69, a small molecule, simultaneously inhibits MDM2 and XIAP, leading to reduced cancer cell growth and increased cell death in liver cancer models.

## Contribution

MX69 is shown to effectively target both MDM2 and XIAP, offering a novel dual-inhibition strategy for hepatocellular carcinoma.

## Key findings

- MX69 reduced cell viability and suppressed colony formation in HUH7 and Hep3B cells.
- MX69 induced oxidative stress, mitochondrial dysfunction, and DNA damage in cancer cells.
- MX69 triggered G0–G1 cell cycle arrest and apoptotic cell death in HCC models.

## Abstract

Genomic instability not only drives tumor initiation and progression but also cooperates with apoptosis resistance to promote therapeutic evasion in hepatocellular carcinoma (HCC). Activation of MDM2, a negative regulator of p53, together with XIAP overexpression, represents a critical axis underlying this resistance. Simultaneous targeting of MDM2 and XIAP by MX69, a small molecule inhibitor, may therefore offer a potent interventional strategy to suppress cell proliferation and enhance pro-apoptotic signaling in HCC in vitro models. To evaluate the effects of MX69, cell viability was assessed via CVDK-8, colony formation, and real-time cell analysis. Oxidative stress levels and DNA damage were examined using fluorescence imaging and comet assays, respectively, while mitochondrial membrane potential was monitored through JC-1 staining. Furthermore, flow cytometry was employed to quantify apoptotic cell death and cell cycle distribution, while Western blot analysis was used to characterize the expression of apoptosis-related proteins. In vitro cytotoxicity assays revealed that MX69 reduced the viability of HUH7 and Hep3B cells in a dose-dependent manner, suppressed colony formation, and exerted anti-proliferative effects in real-time proliferation assays. Cell viability and IC50 values were evaluated using CVDK-8 and RTCA assays. Furthermore, MX69 induced oxidative stress and mitochondrial dysfunction, as evidenced by elevated ROS levels and loss of mitochondrial membrane potential. This was accompanied by significant DNA damage, detected by comet assay and γ-H2AX immunofluorescence, and G0–G1 cell cycle arrest. Moreover, MX69 triggered apoptotic cell death, demonstrating potent anticancer activity. Collectively, our findings identify MDM2/XIAP dual inhibition by MX69 as a promising therapeutic approach in HCC, with potential to overcome apoptosis resistance linked to genomic instability.

## Linked entities

- **Genes:** MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193], XIAP (X-linked inhibitor of apoptosis) [NCBI Gene 331], TP53 (tumor protein p53) [NCBI Gene 7157], H2AXA (Histone superfamily protein) [NCBI Gene 837409]
- **Proteins:** MDM2 (MDM2 proto-oncogene), XIAP (X-linked inhibitor of apoptosis), TP53 (tumor protein p53), H2AXA (Histone superfamily protein)
- **Chemicals:** MX69 (PubChem CID 4075607)
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)

## Full-text entities

- **Genes:** NBN (nibrin) [NCBI Gene 4683] {aka AT-V1, AT-V2, ATV, NBS, NBS1, P95}, BCL2L1 (BCL2 like 1) [NCBI Gene 598] {aka BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52}, H2AX (H2A.X variant histone) [NCBI Gene 3014] {aka H2A.X, H2A/X, H2AFX}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, Anxa5 (annexin A5) [NCBI Gene 11747] {aka Anx5, CPB-I}, H2ax (H2A.X variant histone) [NCBI Gene 15270] {aka H2A.X, H2afx, Hist5-2ax, gammaH2ax}, MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170] {aka BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1}, BIRC2 (baculoviral IAP repeat containing 2) [NCBI Gene 329] {aka API1, HIAP2, Hiap-2, IAP-2, MIHB, RNF48}, Mcl1 (myeloid cell leukemia sequence 1) [NCBI Gene 17210] {aka Gm52627, Mcl-1}, RAD50 (RAD50 double strand break repair protein) [NCBI Gene 10111] {aka NBSLD, RAD502, hRad50}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, Xiap (X-linked inhibitor of apoptosis) [NCBI Gene 11798] {aka 1110015C02Rik, Aipa, Api3, Birc4, IAP3, ILP-1}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, Casp9 (caspase 9) [NCBI Gene 12371] {aka APAF-3, CASP-9, Caspase-9, ICE-LAP6, Mch6}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Mdm2 (MDM2 proto-oncogene) [NCBI Gene 17246] {aka 1700007J15Rik, Mdm-2}, Atm (ataxia telangiectasia mutated) [NCBI Gene 11920] {aka C030026E19Rik}, CASP7 (caspase 7) [NCBI Gene 840] {aka CASP-7, CMH-1, ICE-LAP3, LICE2, MCH3}, XIAP (X-linked inhibitor of apoptosis) [NCBI Gene 331] {aka API3, BIRC4, IAP-3, ILP1, MIHA, XLP2}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, MRE11 (MRE11 double strand break repair nuclease) [NCBI Gene 4361] {aka ATLD, HNGS1, MRE11A, MRE11B}
- **Diseases:** metastasis (MESH:D009362), Cytotoxicity (MESH:D064420), breast cancer (MESH:D001943), TNBC (MESH:D064726), HCC (MESH:D006528), Necrosis (MESH:D009336), injury to (MESH:D014947), prostate cancer (MESH:D011471), melanoma (MESH:D008545), mitochondrial damage (MESH:D028361), lung cancer (MESH:D008175), Cancer (MESH:D009369), carcinogenesis (MESH:D063646), neuroblastoma (MESH:D009447), Damage (MESH:D020263)
- **Chemicals:** BST (-), PI (MESH:D011419), Cisplatin (MESH:D002945), crystal violet (MESH:D005840), JC-1 (MESH:C068624), penicillin (MESH:D010406), SM-164 (MESH:C533467), etoposide (MESH:D005047), CO2 (MESH:D002245), paraformaldehyde (MESH:C003043), agarose (MESH:D012685), MI-219 (MESH:C574930), Nutlin-3 (MESH:C482205), carbocyanine (MESH:D002232), PVDF (MESH:C024865), DMSO (MESH:D004121), ROS (MESH:D017382), NaCl (MESH:D012965), methanol (MESH:D000432), phosphate (MESH:D010710), ethidium bromide (MESH:D004996), NP-40 (MESH:C010615), EDTA (MESH:D004492), agar (MESH:D000362), Triton X-100 (MESH:D017830), YM155 (MESH:C523798), streptomycin (MESH:D013307), water (MESH:D014867), tetrazolium salt (MESH:D013778), E (MESH:D004540), 2',7'-dichlorofluorescein diacetate (MESH:C029569), DTT (MESH:D004229), Sorafenib (MESH:D000077157), acetic acid (MESH:D019342), SDS (MESH:D012967), ethanol (MESH:D000431)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** 3A-C, 4A-C, 7A-C, 6A-C
- **Cell lines:** MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), HUH-7 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0336), U373 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_2818), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), CVDK-8 — Homo sapiens (Human), T-cell prolymphocytic leukemia, Cancer cell line (CVCL_5443), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), MX69 — Mus musculus (Mouse), Hybridoma (CVCL_KC00), Hep3B — Homo sapiens (Human), Childhood hepatocellular carcinoma, Cancer cell line (CVCL_0326)

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940033/full.md

---
Source: https://tomesphere.com/paper/PMC12940033